Israel’s Minovia Therapeutics (see here previously) is testing mitochondria augmentation therapy (MAT) on children with rare, untreatable mitochondrial diseases. It has had some success with Pearson’s Disease sufferers. It may eventually also be able to treat age-related diseases. https://www.israel21c.org/new-cell-therapy-may-be-key-to-curing-disease/

Five Israeli bio-techs at Israel’s MIXiii-Biomed 2018 are developing new therapies for “orphan” (rare) genetic diseases. They include ART Bioscience (Duchenne’s), Eloxx (cystinosis), SpliSense (Cystic Fibrosis), NewStem (Fragile X Syndrome) and Minovia (mitochondrial diseases). https://www.israel21c.org/5-israeli-startups-seeking-cures-for-rare-genetic-diseases/ https://www.artbioscience.com/ http://www.eloxxpharma.com/ http://www.integra-holdings.com/portfolio-items/splisense/ http://www.iati.co.il/company/3793/newstem http://www.iati.co.il/company/3522/minovia-therapeutics … Continue reading →